Edition:
United Kingdom

Cellular Biomedicine Group Inc (CBMG.OQ)

CBMG.OQ on NASDAQ Stock Exchange Global Market

16.53USD
14 Nov 2018
Change (% chg)

$-1.07 (-6.08%)
Prev Close
$17.60
Open
$17.54
Day's High
$17.54
Day's Low
$16.51
Volume
5,129
Avg. Vol
17,939
52-wk High
$25.00
52-wk Low
$10.05

Chart for

About

Cellular Biomedicine Group Inc. is engaged in the development of cell therapy technologies. The Company develops cell therapies for the treatment of cancer and degenerative diseases. The Company conducts immuno-oncology and stem cell clinical trials in China using products from the goods manufacturing practices (GMP) laboratory.... (more)

Overall

Beta: 2.74
Market Cap(Mil.): $147.44
Shares Outstanding(Mil.): 14.11
Dividend: --
Yield (%): --

Financials

  CBMG.OQ Industry Sector
P/E (TTM): -- 85.49 33.64
EPS (TTM): -2.05 -- --
ROI: -41.46 -0.29 14.22
ROE: -41.55 0.40 15.99

Novartis strikes deal with Chinese firm to make Kymriah

ZURICH Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country.

27 Sep 2018

Novartis strikes deal with Chinese firm to make Kymriah

ZURICH Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 (362,663 pounds) gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country.

27 Sep 2018

UPDATE 1-Novartis strikes deal with Chinese firm to make Kymriah

ZURICH, Sept 27 Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country. Local regulations require that Novartis manufactures Kymriah in China if it wants to treat the country's patients with the drug.

27 Sep 2018

Novartis strikes deal with Chinese firm to make Kymriah

ZURICH, Sept 27 Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country.

27 Sep 2018

BRIEF-Cellular Biomedicine Group Enters Into Strategic Licensing And Collaboration Agreement With A Global Leader In Car-T Cell Therapy For Patients In China

* CELLULAR BIOMEDICINE GROUP ENTERS INTO STRATEGIC LICENSING AND COLLABORATION AGREEMENT WITH A GLOBAL LEADER IN CAR-T CELL THERAPY FOR PATIENTS IN CHINA

27 Sep 2018

Earnings vs. Estimates